Where does LPAA stock trade?

Launch One Acquisition Corp. (LPAA) is listed on NASDAQ.

When did Launch One Acquisition Corp. go public?

Launch One Acquisition Corp. (LPAA) completed its IPO in 2024.

How can I track LPAA on Quantisnow?

Quantisnow aggregates Launch One Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LPAA to receive live email and push alerts on every new disclosure.

LPAA

NASDAQ

Launch One Acquisition Corp.

IPO2024

$10.81+0.04 (+0.37%)

News25/Ratings0

Price$10.81+0.16 (+1.50%)

2026-03-042026-06-05

News · 26 weeks15+300%

2025-12-142026-06-07

Mix890d

SEC Filings6(75%)
Insider1(13%)
Other1(13%)

Latest news

25 items

5dSEC
SEC Form PRER14A filed by Launch One Acquisition Corp.
PRER14A - Launch One Acquisition Corp. (0002015502) (Filer)
5dINSIDER
SEC Form 3 filed by new insider Rogers Daniel C
3 - Launch One Acquisition Corp. (0002015502) (Issuer)
5dSEC
SEC Form 8-K filed by Launch One Acquisition Corp.
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
20dSEC
SEC Form PRE 14A filed by Launch One Acquisition Corp.
PRE 14A - Launch One Acquisition Corp. (0002015502) (Filer)
24dSEC
SEC Form 10-Q filed by Launch One Acquisition Corp.
10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
72dSEC
SEC Form 10-K filed by Launch One Acquisition Corp.
10-K - Launch One Acquisition Corp. (0002015502) (Filer)
73dSEC
SEC Form 425 filed by Launch One Acquisition Corp.
425 - Launch One Acquisition Corp. (0002015502) (Subject)
73dSEC
Launch One Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
8-K - Launch One Acquisition Corp. (0002015502) (Filer)
114dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
114dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
115dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
116dSEC
SEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.
SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
117dSEC
SEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.
SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
145dSEC
SEC Form 425 filed by Launch One Acquisition Corp.
425 - Launch One Acquisition Corp. (0002015502) (Subject)
145dPR
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia's core platform technology. Corresponding
200dPR
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that data collected by research teams at Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) featuring the Company's mitochondrial augmentation technology in myelodysplastic syndrome (MDS) will be presented at the 67th American Society of Hematology's (ASH) Annual Meeting and Exposition on December 6-9, 2025 in Orlando, FL. The data will be featured in an oral presentation to be held on Saturday, Dec 6, 2PM ET (abs25-
206dSEC
SEC Form 10-Q filed by Launch One Acquisition Corp.
10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
236dPR
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track Designation in MDS, as well as both Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome. "We continue to receive
263dPR
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting chil
284dSEC
SEC Form 425 filed by Launch One Acquisition Corp.
425 - Launch One Acquisition Corp. (0002015502) (Subject)
285dPR
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers
HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers. Minovia Chief Scientific Officer Dr. Noa Sher, commented, "We are grateful to the Countdown for a Cure Foundation, whose funds are expected to be instrumental in our advancing development of blood-based functional mitochondrial biomarkers. These biomarkers will enab
297dSEC
SEC Form 10-Q filed by Launch One Acquisition Corp.
10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
299dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.
SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
299dSEC
SEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.
SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
318dSEC
SEC Form 425 filed by Launch One Acquisition Corp.
425 - Launch One Acquisition Corp. (0002015502) (Subject)

LPAA FAQ

3 questions

Where does LPAA stock trade?
Launch One Acquisition Corp. (LPAA) is listed on NASDAQ.
When did Launch One Acquisition Corp. go public?
Launch One Acquisition Corp. (LPAA) completed its IPO in 2024.
How can I track LPAA on Quantisnow?
Quantisnow aggregates Launch One Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LPAA to receive live email and push alerts on every new disclosure.